Mostrar el registro sencillo del ítem
Gold Glyconanoparticles Combined with 91–99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors
dc.contributor.author | Terán-Navarro, Hector | |
dc.contributor.author | Zeoli, Andrea | |
dc.contributor.author | Salines-Cuevas, David | |
dc.contributor.author | Marradi, Marco | |
dc.contributor.author | Montoya, Noemí | |
dc.contributor.author | Gonzalez-Lopez, Elena | |
dc.contributor.author | Ocejo-Vinyals, J. Gonzalo | |
dc.contributor.author | Dominguez-Esteban, Mario | |
dc.contributor.author | Gutierrez-Baños, Jose Luis | |
dc.contributor.author | Campos-Juanatey, Felix | |
dc.contributor.author | Yañez-Diaz, Sonsoles | |
dc.contributor.author | Garcia-Castaño, Almudena | |
dc.contributor.author | Rivera, Fernando | |
dc.contributor.author | Duran, Ignacio | |
dc.contributor.author | Álvarez-Domínguez, Carmen | |
dc.date | 2022 | |
dc.date.accessioned | 2023-01-11T09:53:43Z | |
dc.date.available | 2023-01-11T09:53:43Z | |
dc.identifier.issn | 20726694 | |
dc.identifier.uri | https://reunir.unir.net/handle/123456789/13978 | |
dc.description.abstract | This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 nanovaccines showed adjuvant abilities as they induce maturation and activation of monocyte-derived dendritic cells (MoDCs) to functional antigen-presenting cells in healthy donors and patients with melanoma or bladder cancer (BC), promoting a Th1 cytokine pattern. GNP-LLO91–99 nanovaccines were also efficient dendritic cell inducers of immunogenic tumor death using different bladder and melanoma tumor cell lines. The establishment of a pre-clinical mice model of subcutaneous BC confirmed that a single dose of GNP-LLO91–99 nanovaccines reduced tumor burden 4.7-fold and stimulated systemic Th1-type immune responses. Proof of concept assays validated GNP-LLO91–99 nanovaccines as immunotherapy by comparison to anti-CTLA-4 or anti-PD-1 antibodies. In fact, GNP-LLO91–99 nanovaccines increased percentages of CD4+ and CD8+ T cells, B cells, and functional antigen-presenting DCs in tumor-infiltrated lymphocytes, while they reduced the levels of myeloid-derived suppressor cells (MDSC) and suppressor T cells (Treg). We conclude that GNP-LLO91–99 nanovaccines can work as monotherapies or combinatory immunotherapies with anti-CTLA-4 or anti-PD-1 antibodies for solid tumors with high T cell infiltration, such as bladder cancer or melanoma. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Cancers | es_ES |
dc.relation.ispartofseries | ;vol. 14, nº 10 | |
dc.relation.uri | https://www.mdpi.com/2072-6694/14/10/2413 | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | bladder cancer | es_ES |
dc.subject | immunotherapy | es_ES |
dc.subject | listeriolysin O | es_ES |
dc.subject | melanoma | es_ES |
dc.subject | nanoparticles | es_ES |
dc.subject | Scopus | es_ES |
dc.subject | JCR | es_ES |
dc.title | Gold Glyconanoparticles Combined with 91–99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors | es_ES |
dc.type | Articulo Revista Indexada | es_ES |
reunir.tag | ~ARI | es_ES |
dc.identifier.doi | https://doi.org/10.3390/cancers14102413 |